BRISBANE, Calif.--(BUSINESS WIRE)--Apr. 3, 2019--
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced that Jayson Dallas, M.D., President and Chief Executive
Officer, will present at the Needham & Company 18th
Annual Healthcare Conference on Wednesday, April 10, 2019, at 8:00 a.m.
Eastern Time in New York City.
A live webcast of the presentation will be accessible on the Events page
under the Investor Relations section of the Aimmune website at www.aimmune.com.
A replay will also be available following the webcast.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a
biopharmaceutical company developing oral treatments for
life-threatening food allergies. The company’s Characterized
(CODIT™) approach is intended to provide meaningful levels of protection
against allergic reactions resulting from accidental exposure to food
allergens by desensitizing patients with defined, precise amounts of key
allergens. Aimmune’s first investigational biologic product, AR101, is
being developed as a treatment to reduce the risk of anaphylaxis
following accidental exposures to peanut. The BLA for AR101 is under
review by the FDA, which in 2015 granted AR101 Breakthrough Therapy
Designation for the desensitization of peanut-allergic patients 4 to 17
years of age. Aimmune expects to file for marketing approval of AR101 in
Europe in mid-2019. Aimmune has filed an IND application for its second
product, AR201 for the treatment of egg allergy, and intends to start a
randomized phase 2 clinical trial in mid-2019. For more information,
please see www.aimmune.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190403005121/en/
Source: Aimmune Therapeutics, Inc.
(650) 376-5582 or
(650) 376-5583 or